Physician profile

Akshay Avula

Pulmonary Disease · Harrisburg, PA

NPI 1104114776

$552.46

in general payments reported to CMS, 2019-2025

8 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$228.86
Education$99.95

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Astrazeneca Pharmaceuticals LP $119.57 2021
Sanofi-Aventis U.S. LLC $99.95 2024
Daiichi Sankyo INC. $89.44 2024 Enhertu
Novartis Pharmaceuticals Corporation $86.40 2021-2022
Mirati Therapeutics, INC. $74.96 2024 Krazati
Amgen INC. $33.06 2023 Tezspire
Glaxosmithkline, LLC. $31.40 2023 Nucala
Boehringer Ingelheim Pharmaceuticals, INC. $17.68 2021

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Akshay Avula

$552.46

in general payments reported 2019-2025

Years
2021-2024
Top company
Astrazeneca Pharmaceuticals LP

https://glasscript.com/doctor/451713/akshay-avula

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.